Tasigna bests Gleevec in pivotal first-line chronic myeloid leukaemia trial
21 October 2009
Malini Guha
Novartis's Tasigna (nilotinib), its follow-on to its drug Gleevec/Glivec (imatinib), has met its primary endpoint of major molecular response (MMR) in its first Phase III first-line trial designed to show its superiority over the older drug, which has revolutionised the treatment of chronic myeloid...
Please Login to read the full article.
21 October 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pfizer's two cancer candidates accepted for EMA review
- BMS' Sprycel loses out to Novartis' discounted Tasigna in England
- GIST data sign a setback for Tasigna against Glivec as giant Novartis axes trial
- NICE stands by Novartis' cut-price Tasgina over BMS' Sprycel in second-line CML
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
